{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T05:11:53Z","timestamp":1772255513860,"version":"3.50.1"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Photodiagnosis and Photodynamic Therapy"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.pdpdt.2021.102383","type":"journal-article","created":{"date-parts":[[2021,6,5]],"date-time":"2021-06-05T21:23:09Z","timestamp":1622928189000},"page":"102383","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Macular ganglion cell complex changes in eyes treated with aflibercept for neovascular age-related macular degeneration"],"prefix":"10.1016","volume":"35","author":[{"given":"Nazife","family":"A\u015eIKGAR\u0130P","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emine","family":"TEMEL","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kemal","family":"\u00d6RNEK","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.pdpdt.2021.102383_bib0001","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2174\/138945011794182755","article-title":"Age related macular degeneration and visual disability","volume":"12","author":"Christoforidis","year":"2011","journal-title":"Curr. Drug Targets"},{"issue":"3","key":"10.1016\/j.pdpdt.2021.102383_bib0002","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/ICU.0b013e328329b656","article-title":"Safety and efficacy of intravitreal anti-VEGF injections for age-related macular degeneration","volume":"20","author":"Jeganathan","year":"2009","journal-title":"Curr. Opin. Ophthalmol."},{"issue":"14","key":"10.1016\/j.pdpdt.2021.102383_bib0003","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.pdpdt.2021.102383_bib0004","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ophtha.2005.11.019","article-title":"Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration","volume":"113","author":"Avery","year":"2006","journal-title":"Ophthalmology"},{"issue":"20","key":"10.1016\/j.pdpdt.2021.102383_bib0005","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"Research Group","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.pdpdt.2021.102383_bib0006","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ajo.2012.04.020","article-title":"Aflibercept for age-related macular degeneration: a game-changer or quiet addition?","volume":"154","author":"Browning","year":"2012","journal-title":"Am. J. Ophthalmol."},{"issue":"2","key":"10.1016\/j.pdpdt.2021.102383_bib0007","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ajo.2014.10.035","article-title":"Risk factors for geographic atrophy after intravitreal ranibizumab injections for retinal angiomatous proliferation","volume":"159","author":"Cho","year":"2015","journal-title":"Am. J. Ophthalmol."},{"issue":"3","key":"10.1016\/j.pdpdt.2021.102383_bib0008","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1167\/iovs.14-16204","article-title":"Scleral thinning after repeated intravitreal injections of antivascular endothelial growth factor agents in the same quadrant","volume":"56","author":"Zinkernagel","year":"2015","journal-title":"Invest Ophthalmol. Vis. Sci."},{"issue":"1","key":"10.1016\/j.pdpdt.2021.102383_bib0009","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2353\/ajpath.2007.061237","article-title":"Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury","volume":"171","author":"Nishijima","year":"2007","journal-title":"Am. J. Pathol."},{"issue":"3","key":"10.1016\/j.pdpdt.2021.102383_bib0010","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/IAE.0b013e3181909404","article-title":"Bevacizumab is not toxic to retinal ganglion cells after repeated intravitreal injection","volume":"29","author":"Cheng","year":"2009","journal-title":"Retina"},{"issue":"4","key":"10.1016\/j.pdpdt.2021.102383_bib0011","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.ajpath.2012.12.032","article-title":"VEGF-A is necessary and sufficient for retinal neuroprotection in models of experimental glaucoma","volume":"182","author":"Foxton","year":"2013","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.pdpdt.2021.102383_bib0012","first-page":"1848","article-title":"Bevacizumab neutralizes the protective effect of vascular endothelial growth factor on retinal ganglion cells","volume":"16","author":"Brar","year":"2010","journal-title":"Mol. Vis."},{"key":"10.1016\/j.pdpdt.2021.102383_bib0013","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3341\/kjo.2017.0054","article-title":"Effect of anti-vascular endothelial growth factor antibody on the survival of cultured retinal ganglion cells","volume":"31","author":"Lee","year":"2017","journal-title":"Korean J. Ophthalmol."},{"key":"10.1016\/j.pdpdt.2021.102383_bib0014","doi-asserted-by":"crossref","first-page":"449","DOI":"10.4103\/2008-322X.150815","article-title":"Changes in retinal nerve fiber layer thickness after two intravitreal bevacizumab injections for wet type age-related macular degeneration","volume":"9","author":"Entezari","year":"2014","journal-title":"J. Ophthalmic Vis. Res."},{"key":"10.1016\/j.pdpdt.2021.102383_bib0015","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.ajo.2010.04.029","article-title":"Retinal nerve fiber layer thickness in patients receiving chronic anti-vascular endothelial growth factor therapy","volume":"150","author":"Horsley","year":"2010","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.pdpdt.2021.102383_bib0016","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ajo.2016.04.003","article-title":"Retinal ganglion cell layer change in patients treated with anti-vascular endothelial growth factor for neovascular age-related macular degeneration","volume":"167","author":"Beck","year":"2016","journal-title":"Am. J. Ophthalmol."},{"issue":"8","key":"10.1016\/j.pdpdt.2021.102383_bib0017","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1111\/j.1755-3768.2008.01175.x","article-title":"Ischaemic change after intravitreal bevacizumab (Avastin) injection for macular oedema secondary to non-ischaemic central retinal vein occlusion","volume":"86","author":"Kim","year":"2008","journal-title":"Acta Ophthalmol."},{"issue":"6","key":"10.1016\/j.pdpdt.2021.102383_bib0018","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1017\/S0952523800005666","article-title":"N-methyl-D-aspartate-induced neurotoxicity in the adult rat retina","volume":"8","author":"Siliprandi","year":"1992","journal-title":"Vis. Neurosci."},{"key":"10.1016\/j.pdpdt.2021.102383_bib0019","doi-asserted-by":"crossref","first-page":"3976","DOI":"10.1167\/iovs.15-17013","article-title":"Ganglion cell\u2013inner plexiform layer and peripapillary retinal nerve fiber layer thicknesses in age-related macular degeneration","volume":"56","author":"Lee","year":"2015","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.pdpdt.2021.102383_bib0020","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.ajo.2015.05.030","article-title":"Macular ganglion cell complex and retinal nerve fiber layer comparison in different stages of age-related macular degeneration","volume":"160","author":"Zucchiatti","year":"2015","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.pdpdt.2021.102383_bib0021","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1097\/IJG.0000000000000776","article-title":"Rate of macular ganglion cell-inner plexiform layer thinning in glaucomatous eyes with vascular endothelial growth factor inhibition","volume":"26","author":"Lee","year":"2017","journal-title":"J. Glaucoma"}],"container-title":["Photodiagnosis and Photodynamic Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1572100021002106?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1572100021002106?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:39:02Z","timestamp":1761611942000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1572100021002106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":21,"alternative-id":["S1572100021002106"],"URL":"https:\/\/doi.org\/10.1016\/j.pdpdt.2021.102383","relation":{},"ISSN":["1572-1000"],"issn-type":[{"value":"1572-1000","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Macular ganglion cell complex changes in eyes treated with aflibercept for neovascular age-related macular degeneration","name":"articletitle","label":"Article Title"},{"value":"Photodiagnosis and Photodynamic Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pdpdt.2021.102383","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102383"}}